Antibody has developed among 93 per cent of those who have received both doses of the Oxford-AstraZeneca (Covishield) Covid-19 vaccine in Bangladesh, according to a study.
The Department of Microbiology at Dhaka Medical College (DMC) conducted the study on 308 people who took the vaccine, developed by Oxford University and AstraZeneca and manufactured by the Serum Institute of India (SII).The findings of the study were revealed at a function at the Dhaka Medical College Hospital (DMCH) on Sunday.
At the programme, head of the DMC Microbiology department Prof Dr SM Shamsuzzaman, who led the survey, said they collected samples for antibody tests twice -- after each dose of the vaccine.
Four weeks after the first shot, they found antibody among 41 per cent of the recipients, he said, adding that they took samples two weeks after the second dose was administered but within four weeks and tested those. “This time 93 per cent of the recipients were found with antibody,” Shamsuzzaman said.
Researchers, however, said the results cannot be generalised for all who have been vaccinated fully.
Antibody tests were conducted on 308 fully vaccinated individuals, who are doctors, nurses and other employees of the DMCH.
All the volunteers of the research were aged over 30 years and under 60 years while 80 per cent of them were aged between 40-50 years, Shamsuzzaman said.Of the total samples, 70 per cent was of teachers, 10 per cent of DMCH staff and the rest of medical officers and others.
“We needed to know whether this vaccine would work at all, what would happen after the first dose, what would happen after the second dose and whether antibody would develop. So, we launched this study,” the DMC Microbiology department head said about the motive of the research.
He said once produced, antibody may remain in the human body for six months although the researchers did not have exact information about the matter.
DMC Principal Prof Dr Md Titu Miah said further studies will determine whether booster doses are required or not.
Bangladesh started its nationwide vaccination against Covid-19 on February 7 last with the Covishield jab.